Cashu Logo
HomeWatchlistNewsSignalsPicks
DJI
-1.23%
SPX
-1.60%
IXIC
-2.24%
FTSE
-0.70%
N225
-0.66%
AXJO
-0.92%
Cashu Logo
Log In
HomeWatchlistNewsSignalsPicks
Stocks
0.00 (0.00%)
0.000
USD
At close at --,----
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

  • About Us
  • Careers
  • Blog
  • News

Help & Support

  • Help Center
  • Contact Us
  • Pro Support

Legal

  • Privacy Policy
  • Terms of Use
InstagramYouTube

© 2024 Cashu PTY LTD.

Join our newsletter to keep up to date with us!

Overview

Loading chart...

About

What does ATAI do?
ATAI Life Sciences NV, a Berlin-based clinical-stage biopharmaceutical company, focuses on developing treatments for mental health disorders and went public on June 18, 2021. Key compounds include PCN-101 for treatment-resistant depression and DMX-1002 for opioid use disorder.
Sector
💻 Health Care
IPO
CEO
Employees
83 employees
Headquarters
New York, USA
Website
http://www.atai.life

Recently from Cashu

publisher logo
Cashu

ATAI Life Sciences N.V.: Pioneering the Future of Psychedelic Medicine and Mental Health Treatment

2 days ago
publisher logo
Cashu

ATAI Life Sciences Leads Psychedelic Research Amid Growing Market Optimism for Mental Health Solutions

4 days ago
publisher logo
Cashu

ATAI Life Sciences N.V. Advances Psychedelic Research for Treatment-Resistant Depression with BPL-003

29 days ago

Key Stats

Market Cap
826.94M
Dividend Yield
0.00%
P/E Ratio
-31.29
EPS
-0.93
Revenue
308.00K
Avg. Volume
9.12M
Stocks
Health Care
atai
ATAI Life Sciences N.V.
NASDAQ: ATAI
+0.07 (+1.71%)
4.17
USD
At close at Aug 01, 20:40 UTC
Summary
News
Signals
Benchmarks
Financials